LIPOCINE INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
LIPOCINE INC. (LPCN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $18.34 per share for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-12.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2015-11-12
- LIPOCINE INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2015-03-31 was $0.00, a 100.00% decline year-over-year.
- LIPOCINE INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2014-03-31 was $12.84.
- LIPOCINE INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2014 was $12.84, a 14.13% increase from fiscal 2013.
- LIPOCINE INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2013 was $11.25.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2015-09-30 | $18.34 10-Q · filed 2015-11-12 | |||
| 2015-06-30 | $18.34 10-Q · filed 2015-08-11 | |||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-07 | |||
| 2014-12-31 | $12.84 10-K · filed 2015-03-11 | |||
| 2014-09-30 | $12.84 10-Q · filed 2014-11-10 | |||
| 2014-06-30 | $12.84 10-Q · filed 2014-08-13 | |||
| 2014-03-31 | $12.84 10-Q · filed 2014-05-13 | |||
| 2013-12-31 | $11.25 10-K · filed 2014-03-31 | |||
| 2013-09-30 | $4.85 10-Q · filed 2013-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |